Last updated on April 20, 2014 at 17:20 EDT

Latest Macrocure Stories

2013-03-14 08:28:12

PETACH TIKVA, Israel, March 14, 2013 /PRNewswire/ -- Macrocure (http://www.macrocure.com), a biotechnology company developing advanced cell therapy products, announced today that the European Patent Office (EPO) intends to grant a European patent covering Marcocure's flagship product, CureXcell(R). The patent will be officially granted under an application titled "Activate Leukocyte Composition" and will provide patent coverage for CureXcell(R) in Europe through March 2030....

Macrocure’s CureXcell Targets Hard-To-Heal Wounds
2012-06-21 08:53:18

Connie K. Ho for redOrbit.com Chronic wounds are a growing issue. Luckily, Macrocure´s CureXcell addresses that issue. Macrocure, a biotechnology company that specializes in cell therapy for hard-to-heal wounds, is currently conducting a multi center Phase III study in North America and Israel under a Special Protocol Assessment for lower extremity chronic ulcers for adults with diabetes. Macrocure´s lead product is CureXCell, an approach to treating hard-to-heal wounds by...